Conversion of D-leucine (CAS 328-38-1) to Fmoc-D-Leu-OH for solid-phase synthesis of D-Leu-containing peptide APIs proceeds through N-protection under Schotten-Baumann conditions. The free amino acid is dissolved in 10% Na₂CO₃ and adjusted to 0–5 °C before addition of Fmoc-OSu in acetone at a molar ratio of 1.2 mol Fmoc-OSu per mol D-leucine. The reaction is held for 12 h at 20 °C, quenched with 1 M HCl, and extracted with ethyl acetate. Crude Fmoc-D-Leu-OH is recrystallized from ethyl acetate/heptane and isolated via vacuum filter-dryer. Residual free D-leucine is controlled below 0.3% by reversed-phase HPLC after pre-column derivatization. This protection step is performed in glass-lined reactors under nitrogen to limit Fmoc decomposition; exposure to atmospheric moisture in production zones above 60% relative humidity increases free D-leucine carryover and reduces coupling efficiency on subsequent resin loading.

For solid-phase synthesis, the derivative is attached to 2-chlorotrityl chloride resin with substitution of 0.8–1.2 mmol/g. A loading ratio of 4 equiv Fmoc-D-Leu-OH in dichloromethane with 8 equiv DIPEA is used. After 45 min, unreacted sites are capped with methanol. Each subsequent coupling uses 3.95 equiv Fmoc-amino acid, 3.8 equiv HATU, and 8 equiv DIPEA in DMF. The activation time of Fmoc-D-Leu-OH with HATU is limited to 2 min before addition to the resin; prolonged activation promotes oxazolone formation and partial racemisation. Deprotection is performed with 20% piperidine/DMF for 20 min. Ninhydrin monitoring confirms completion at each step. DMF is pre-dried to <100 ppm water because residual moisture accelerates premature Fmoc loss and cap occurrence on synthesis-scale batches.

End-product classes are D-Leu-containing linear and cyclic antimicrobial peptide candidates, including polymyxin-type structures and synthetic intermediates in which D-Leu at position 2 confers reduced trypsin susceptibility as measured by peptide mapping following 2 h trypsin exposure at 37 °C. The crude peptide is cleaved with TFA/TIS/H₂O 95:2.5:2.5, precipitated in cold diethyl ether, and dried under vacuum at 20 °C. Compliance for the Fmoc derivative under ICH Q7 includes assay by HPLC ≥98.0%, L-Leu enantiomer by Chiralpak MA(+) ≤0.5%, water by Karl Fischer ≤0.5%, and residual solvents by USP <467>. The L-Leu contaminant is process-relevant because it competes for resin loading and cannot be removed after incorporation into the protected amino acid intermediate.

How Is D-Leucine Quantified as an Enantiomeric Impurity in L-Leucine Pharmacopoeial Release?

L-Leucine drug substance specifications require control of the D-enantiomer as a chiral impurity. A standard addition method injects L-leucine solution spiked with D-leucine at 0.5% and 1.0% relative area. The separation is performed on a Chirobiotic T teicoplanin column (250 × 4.6 mm, 5 µm) with mobile phase of methanol/water 75:25 containing 0.1% formic acid and 0.1% diethylamine. Flow rate is 1.0 mL/min and column temperature 25 °C. Detection at 200 nm gives a resolution between L- and D-leucine of not less than 1.5. The chiral recognition depends on the teicoplanin aglycone binding pocket and requires equilibration of the column for at least 30 min before system suitability injections.

System suitability follows USP <621> and method validation under ICH Q2(R1). Spike recovery at 0.5% is 90–110%. Limit of detection for D-leucine is 0.05% relative to L-leucine. The method is applied in quality control of amino acid infusion APIs and L-leucine oral solid dosage forms. D-Leucine reference material is stored in a tight container at 20–25 °C and re-qualified every 24 months. Water content of the reference material by Karl Fischer is ≤0.5% to prevent esterification artifacts. The end product of this analytical application is not a formulated dosage form but a release certificate with enantiomeric purity data supporting individual batch approval against Ph. Eur. 2.2.7 and USP <781> optical rotation acceptance criteria.

Fed-batch biotransformation systems expressing porcine kidney D-amino acid oxidase are supplied with D-leucine as a defined substrate for the production of 4-methyl-2-oxopentanoic acid, the branched-chain keto acid used in metabolic disorder screening. The oxidative deamination consumes 1 mol D-leucine and 1 mol O₂ per mol keto acid, releasing 1 mol H₂O₂ and 1 mol NH₃. Catalase is co-immobilized at 5,000 U/L to decompose H₂O₂ because accumulation above 10 mM irreversibly damages the flavin cofactor. Process conditions use 100 mM D-leucine in 50 mM sodium pyrophosphate buffer, pH 8.3, at 25 °C. Aeration rate is set to maintain dissolved oxygen above 30% air saturation; oxygen transfer is frequently the rate-limiting factor in high-cell-density runs.

Product recovery uses cation-exchange resin to remove unreacted D-leucine, followed by ethyl acetate extraction at pH 2.0. Distillation yields 4-methyl-2-oxopentanoic acid as a clear viscous liquid. Analytical release by HPLC with UV detection at 210 nm requires purity ≥97.0%. Residual D-leucine is ≤1.0%. The keto acid product is used as a reference standard in mass spectrometry panels for maple syrup urine disease; its commutability with matrix-based clinical calibrators is evaluated against ISO 17511. Published data for scale-up beyond 10 L reactor volume using this specific D-leucine oxidase configuration are limited, so process transfer requires pilot confirmation of catalase half-life under repeated D-leucine feeds.

Ring-Opening Polymerisation of D-Leucine N-Carboxyanhydride to Copolypeptide Excipients

D-Leucine is converted to its N-carboxyanhydride for ring-opening polymerisation of polypeptide drug delivery vehicles. The amino acid is suspended in anhydrous THF under argon and treated with triphosgene at a molar ratio of 1.05–1.20 mol carbonyl source per mol D-leucine. The reaction is heated to 60 °C for 3 h. The NCA is precipitated in cold hexane and stored under argon at -20 °C; water content by Karl Fischer must remain <50 ppm because moisture initiates uncontrolled polymerisation during storage. Ring-opening polymerisation is initiated by 0.05 mol% benzylamine in DMF at 25 °C, yielding poly(D-leucine) with a target degree of polymerisation of 100–200.

Polymerisation kinetics follow first-order consumption of NCA; the apparent rate constant in DMF at 25 °C depends on residual water and amine initiator concentration. Block copolypeptides are produced by sequential addition of D-leucine NCA and a second NCA such as γ-benzyl-L-glutamate NCA. The resulting amphiphilic copolypeptides form self-assembled vesicles for hydrophobic drug loading. Residual D-leucine NCA in the final product is monitored by gel permeation chromatography with multi-angle light scattering. End-product specifications include dispersity <1.3, residual monomer <0.5% by FTIR carbonyl intensity, and heavy metal content <10 ppm by ICP-MS. Compliance is research-grade until a specific formulation enters preclinical development; then ICH Q7 applies to the NCA intermediate.

When D-Leucine Is Added to Copper(II) Mobile Phases for Chiral Ligand-Exchange Chromatography

In chiral ligand-exchange HPLC, D-leucine acts as a chiral selector ligand for the separation of underivatized racemic amino acids. The mobile phase is prepared by mixing 2 mM CuSO₄ and 4 mM D-leucine in water/acetonitrile 90:10, adjusted to pH 4.5 with acetate buffer. The binary Cu(D-leucine)₂ complex forms dynamically and interacts with analytes through ligand exchange at the Cu(II) centre. Separation is run on a conventional octadecylsilane column (150 × 4.6 mm, 5 µm) at 25 °C with UV detection at 230 nm. The method resolves selected D/L pairs but is sensitive to column temperature fluctuations; retention time drift beyond 3% occurs if the mobile phase temperature is not controlled.

This application is used in method development for amino acid racemate screening, not as a stability-indicating pharmacopoeial method. The mobile phase must be freshly prepared every 24 h because Cu(II)-D-leucine complexes undergo slow precipitation above pH 5.5. D-Leucine purity ≥99.0% is required because L-leucine contamination shifts chiral resolution below baseline. The chromatographic output is a separation method with resolution ≥1.5 for selected aliphatic amino acid pairs; the method is validated for selectivity and limit of quantification following ICH Q2(R1), but robustness with respect to CuSO₄ source and column batch remains a critical operational limitation.

In preparation of D-amino acid aminotransferase from Bacillus subtilis, D-leucine is supplied as one of several amino donors to discriminate substrate selectivity. The enzyme is induced in a defined medium containing 5 g/L D-leucine, 2 g/L sodium glutamate, 0.5 g/L MgSO₄·7H₂O, and 0.1 g/L pyridoxal 5′-phosphate. Fermentation runs at 37 °C, pH 7.0, and 1 vvm aeration for 18 h. The intracellular enzyme is released by high-pressure homogenisation at 800 bar and purified by ammonium sulfate fractionation between 35% and 70% saturation. D-Leucine is not a rate-limiting carbon source; it functions as an enzyme inducer and chiral amino donor in the transamination half-reaction.

The resulting D-amino acid aminotransferase preparation is used for synthesis of D-phenylalanine and D-tryptophan via asymmetric transamination of the corresponding keto acids. The specific activity of the enzyme is tested with D-leucine and pyruvate; one unit is defined as the amount that produces 1 µmol D-alanine per min at 37 °C and pH 8.0. End-product enzyme solutions are stabilized with 20% glycerol and stored at -20 °C. Residual D-leucine in the final enzyme preparation is held below 0.1 mM by ultrafiltration because carryover into downstream transamination reactions would distort product chiral purity calculations. Published fermentation data for this specific D-leucine-containing induction medium are limited to laboratory-scale batches, and transfer to production-scale bioreactors requires confirmation of oxygen transfer in high-density Bacillus cultures.